Snowball logo
logo
ALT_logo

Altimmune Inc

$3.00+$0.06  (2.04%)
Estimate
EPS
-0.75
Beta
0.169
Growth
Net income, YoY
-3.07%
FCF, YoY
-25.27%
Forecast
EPS (FWD)
-0.692
About the company
Ticker
ALT
ISIN
US02155H2004
Country
United States of America
Sector (GICS)
Healthcare
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

What sector does Altimmune Inc (ALT) operate in?

Altimmune Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Altimmune Inc (ALT) current stock price?

As of the latest data, Altimmune Inc stock price is $3.00, with a previous close of $2.94. Altimmune Inc gained $0.06 in the last trading session, representing a 2.04% increase.

What is Altimmune Inc (ALT) current market capitalization?

Altimmune Inc market cap is approximately 583.55 million.

What is Altimmune Inc (ALT) Earnings Per Share (EPS)?

The trailing EPS is -$0.75, and the forward EPS is -$0.69.

What is Altimmune Inc (ALT) EBITDA?

Altimmune Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -26.20 million.

Does Altimmune Inc (ALT) pay dividends?

No. Altimmune Inc does not pay a dividend.

What is Altimmune Inc (ALT) beta (volatility) score?

Altimmune Inc has a beta of 0.169, indicating lower volatility than the overall market.